SUBSCRIBE
SUBSCRIBE

AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.

We are AbbVie. A global Fortune 500 biopharmaceutical company creating life-changing medicines and first-in-kind solutions that make a real difference in people’s lives.

Our 50,000+ employees across geographies, disciplines, and therapeutic areas put impact at the core of every decision. With over $50B invested in R&D since our founding in 2013, we’re always focused on helping people and communities thrive for generations to come.

  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
1 North Waukegan Road
North Chicago, IL 60064
Tel: 1-800-255-5162
Visit website
Email Us
Stock Symbol: ABBV
Stock Exchange: NYSE
  • Featured Employer
NEWS
AbbVie's office in South San Francisco, California
Cancer
AbbVie Scoops Up Ichnos Glenmark’s Lead Myeloma Antibody for Nearly $2B
The deal, which involves a $700 million upfront payment, gives AbbVie access to ISB 2001, a clinical-stage first-in-class trispecific antibody currently being tested for certain kinds of multiple myeloma as well as autoimmune indications.
July 10, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Podcast
Second Half Milestones, KalVista’s Surprise Approval, Another RFK Jr. Lawsuit, More
H2 2025 catalysts to watch, biopharma implications of President Trump’s tax law, KalVista’s new hereditary angioedema drug that Marty Makary reportedly tried to reject, another lawsuit aimed at Health Secretary Robert F. Kennedy Jr. and a plea from patients with ALS for access to BrainStorm’s NurOwn.
July 9, 2025
 · 
1 min read
 · 
Heather McKenzie
Pictured: Office building science collage
Career Advice
The Top 12 Companies Hiring in Biopharma Now
Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.
July 3, 2025
 · 
1 min read
 · 
Angela Gabriel
Podcast
CAR T Expands, M&A Ticks Up, Two Psychedelics Read Out, and the Supreme Court Rules on PrEP
The high court sides with HHS on HIV PrEP drugs; Health Secretary RFK Jr.’s newly appointed CDC vaccine advisors discuss thimerosal in flu vaccines, skip vote on Moderna’s mRNA-based RSV vaccine; FDA removes CAR T guardrails; AbbVie snaps up Capstan for $1.2B to end first half; and psychedelics take off again with data from Compass and Beckley.
July 2, 2025
 · 
1 min read
 · 
Heather McKenzie
Contemporary art collage, female palms in the orange circle, a bag of money. Concept of business and finance.
Mergers & acquisitions
AbbVie Plunks Down $2.1B for Capstan and Its Novel CAR T Therapies
The all-cash buyout, which gives AbbVie access to Capstan Therapeutics’ in vivo edited CAR T therapy for B cell–mediated autoimmune diseases, adds to a growing sense of momentum in M&A, according to BMO Capital Markets.
June 30, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Facade of the FDA's office in Maryland
Approvals
Moderna, Merck, UroGen, Score RSV and Cancer Nods in June
The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an approval in bladder cancer, and more key regulatory nods from the past month.
June 30, 2025
 · 
9 min read
 · 
Tristan Manalac
vector illustration arrows miss the target board, concept of lost in focus, failure, fail, mistake
Cancer
Roche, AbbVie’s Venclexta Stumbles Again, This Time in Myelodysplastic Syndromes
Venclexta, when combined with azacitidine, elicited an overall survival benefit below 10% in patients with myelodysplastic syndromes.
June 17, 2025
 · 
1 min read
 · 
Tristan Manalac
Hiring collage showing HR checking applicant information
Job Trends
Hiring Outlook: Indiana, California Top 2 Hot Spots for Jobs in May
The biopharma job market failed to turn around in May, but employers were still hiring, especially in Indiana and California, based on BioSpace data. The two states had the most job postings live on BioSpace last month, with Indiana showing a 108% year-over-year increase.
June 12, 2025
 · 
4 min read
 · 
Angela Gabriel
Aerial panorama of Trenton New Jersey skyline and state capitol at sunset. Trenton is the capital city of the U.S. state of New Jersey and the county seat of Mercer County.
Job Trends
9 Companies Hiring in New Jersey
Looking for a new opportunity in New Jersey? These nine companies have open roles that could be a great fit for you.
June 12, 2025
 · 
1 min read
 · 
Chantal Dresner
Load More
JOBS
View All Jobs at AbbVie
IN THE PRESS
Press Releases
AbbVie and Ichnos Glenmark Innovation (IGI) Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
July 11, 2025
 · 
7 min read
Press Releases
AbbVie to Host Second-Quarter 2025 Earnings Conference Call
July 1, 2025
 · 
1 min read
Press Releases
AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology
June 30, 2025
 · 
6 min read
Press Releases
Elahere Market Opportunities and Strategies to 2034: Abbvie Secures European Approval for Elahere in Platinum-Resistant Ovarian Cancer
June 25, 2025
 · 
7 min read
Press Releases
AbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention
June 18, 2025
 · 
10 min read
Press Releases
AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes
June 17, 2025
 · 
10 min read
Press Releases
Genentech Provides Update on Phase III Verona Study
June 16, 2025
 · 
8 min read
Press Releases
U.S. FDA Approves Expanded Indication for AbbVie’s MAVYRET® (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus
June 11, 2025
 · 
11 min read
Press Releases
Enanta Pharmaceuticals’ Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus
June 11, 2025
 · 
11 min read
Press Releases
AbbVie Invites People Living with Migraine to Enter the Second Annual AbbVie Migraine Career Catalyst Award™ Contest to Support Their Professional Goals
June 3, 2025
 · 
5 min read
Load More